TY - JOUR

T1 - Minimum inhibitory concentrations of aztreonam–avibactam, ceftazidime–avibactam and meropenem in clinical isolates of Klebsiella pneumoniae harboring carbapenemase genes

AU - Ageevets, V.

AU - Sulian, O.

AU - Avdeeva, A.

AU - Chulkova, P.

AU - Ageevets, I.

AU - Gostev, V.

AU - Alieva, K.

AU - Golikova, M.

AU - Sidorenko, S.

N1 - Export Date: 19 October 2024 CODEN: JANTA Адрес для корреспонденции: Ageevets, V.; Pediatric Research and Clinical Center for Infectious DiseasesRussian Federation; эл. почта: ageevets@list.ru Химические вещества/CAS: avibactam plus ceftazidime, 1393723-27-7; meropenem, 96036-03-2; serine, 56-45-1, 6898-95-9; avibactam, 1192500-31-4, 1192491-61-4; aztreonam, 78110-38-0; beta lactamase, 9073-60-3; ceftazidime, 72558-82-8, 73547-61-2, 78439-06-2; Anti-Bacterial Agents; avibactam; avibactam, ceftazidime drug combination; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; carbapenemase; Ceftazidime; Drug Combinations; Meropenem Производители: Sigma Aldrich, United States Сведения о финансировании: Russian Science Foundation, RSF, 21-74-10090 Сведения о финансировании: Russian Science Foundation, RSF Текст о финансировании 1: This research was funded by the Russian Science Foundation, grant number 21-74-10090.

PY - 2024/7/1

Y1 - 2024/7/1

N2 - This study was aimed at understanding the distributions of the MICs (minimum inhibitory concentrations) of aztreonam–avibactam, ceftazidime–avibactam and meropenem with respect to Klebsiella pneumoniae isolates producing different types of carbapenemases and their combinations. K. pneumoniae isolates were collected between 2019 and 2022 from 37 hospitals. PCR was used to screen for blaKPC-, blaNDM- and blaOXA-48-like genes. MICs were determined by the broth microdilution method for meropenem, aztreonam–avibactam and ceftazidime–avibactam at a constant avibactam concentration of 4 mg l−1. MIC distributions were analyzed for groups of isolates based on the identified carbapenemases including their combinations. The AZT/AVI MIC50 and MIC90 for all NDM-positive isolates were 0.25 and 0.5, respectively, and for serine-carbapenemase-only producers, they were 0.25 and 1 mg l−1, respectively. The CZD/AVI MIC50 and MIC90 values for serine-carbapenemase-only producers were 1 and 4 mg l−1, respectively. The AZT/AVI MIC50 and MIC90 values for co-producers and single carbapenemase producers were the same (i.e., 0.25 and 1 mg l−1, respectively). The total proportion of meropenem-susceptible isolates (≤8 mg l−1) among all the carbapenemase producers was 25.1% (31.1% among single-carbapenemase producers and 9.2% among co-producers). The results support the use of aztreonam–avibactam for the empirical treatment of infections caused by any carbapenemase producers. © The Author(s), under exclusive licence to the Japan Antibiotics Research Association 2024.

AB - This study was aimed at understanding the distributions of the MICs (minimum inhibitory concentrations) of aztreonam–avibactam, ceftazidime–avibactam and meropenem with respect to Klebsiella pneumoniae isolates producing different types of carbapenemases and their combinations. K. pneumoniae isolates were collected between 2019 and 2022 from 37 hospitals. PCR was used to screen for blaKPC-, blaNDM- and blaOXA-48-like genes. MICs were determined by the broth microdilution method for meropenem, aztreonam–avibactam and ceftazidime–avibactam at a constant avibactam concentration of 4 mg l−1. MIC distributions were analyzed for groups of isolates based on the identified carbapenemases including their combinations. The AZT/AVI MIC50 and MIC90 for all NDM-positive isolates were 0.25 and 0.5, respectively, and for serine-carbapenemase-only producers, they were 0.25 and 1 mg l−1, respectively. The CZD/AVI MIC50 and MIC90 values for serine-carbapenemase-only producers were 1 and 4 mg l−1, respectively. The AZT/AVI MIC50 and MIC90 values for co-producers and single carbapenemase producers were the same (i.e., 0.25 and 1 mg l−1, respectively). The total proportion of meropenem-susceptible isolates (≤8 mg l−1) among all the carbapenemase producers was 25.1% (31.1% among single-carbapenemase producers and 9.2% among co-producers). The results support the use of aztreonam–avibactam for the empirical treatment of infections caused by any carbapenemase producers. © The Author(s), under exclusive licence to the Japan Antibiotics Research Association 2024.

KW - avibactam plus aztreonam

KW - avibactam plus ceftazidime

KW - carbapenemase

KW - meropenem

KW - serine

KW - antiinfective agent

KW - avibactam

KW - avibactam, ceftazidime drug combination

KW - azabicyclo derivative

KW - aztreonam

KW - bacterial protein

KW - beta lactamase

KW - ceftazidime

KW - antibiotic sensitivity

KW - Article

KW - bacterium isolate

KW - broth dilution

KW - controlled study

KW - Japan

KW - Klebsiella pneumoniae

KW - MIC50

KW - MIC90

KW - minimum inhibitory concentration

KW - nonhuman

KW - drug combination

KW - drug effect

KW - drug therapy

KW - genetics

KW - human

KW - Klebsiella infection

KW - metabolism

KW - microbial sensitivity test

KW - microbiology

KW - Anti-Bacterial Agents

KW - Azabicyclo Compounds

KW - Aztreonam

KW - Bacterial Proteins

KW - beta-Lactamases

KW - Ceftazidime

KW - Drug Combinations

KW - Humans

KW - Klebsiella Infections

KW - Meropenem

KW - Microbial Sensitivity Tests

UR - https://www.mendeley.com/catalogue/5b9c9697-78b0-3715-a044-113295979334/

U2 - 10.1038/s41429-024-00758-8

DO - 10.1038/s41429-024-00758-8

M3 - статья

VL - 77

SP - 706

EP - 710

JO - Journal of Antibiotics

JF - Journal of Antibiotics

SN - 0021-8820

IS - 10

ER -